Premium
Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I‐PRESERVE trial
Author(s) -
McMurray John J.V.,
Carson Peter E.,
Komajda Michel,
McKelvie Robert,
Zile Michael R.,
Ptaszynska Agata,
Staiger Christoph,
Donovan J. Mark,
Massie Barry M.
Publication year - 2008
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1016/j.ejheart.2007.12.010
Subject(s) - heart failure , medicine , ejection fraction , cardiology , clinical trial , stroke volume
Background: We describe the baseline characteristics of subjects randomised in the largest placebo‐controlled, morbidity‐mortality trial to date in patients with heart failure and preserved ejection fraction — the irbesartan in heart failure with preserved systolic function trial (I‐PRESERVE). Methods and results: 4133 patients with a mean age of 72 years (a third were 75 years or older) were randomised and 60% were women. The mean (SD) LVEF was 59 (9)% and almost 80% of patients were in NYHA Class III or IV. Approximately 80% of patients were also overweight or obese. Heart failure was reported by investigators to have a hypertensive aetiology in 64% of patients. Prior myocardial infarction was relatively uncommon (24%), as was coronary revascularisation (13%). Atrial fibrillation and diabetes each occurred in between a quarter and a third of patients. The following treatments were used at baseline: diuretic 83%, beta‐blocker 59%, calcium channel blocker 40%, ACE inhibitor 25%, spironolactone 15% and digoxin 14%. Conclusions: Patients in I‐PRESERVE are broadly representative of those seen in epidemiological studies and, because of this, the results of this trial should be generally applicable to “real world” patients with heart failure and preserved ejection fraction.